Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.46 |
| ▸ | ERN1 | O75460 | 5/20 | 0.44 |
| ▸ | HTT | P42858 | 3/20 | 0.44 |
| ▸ | RAB9A | P51151 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 4/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
| ▸ | PRKDC | P78527 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29957037 | 1.00 | ALDH1A1 (0.46) | ALDH1A1ERN1HTTRAB9AMAPT | |
| SCHEMBL29955136 | 0.85 | ERN1 (0.44) | ALDH1A1ERN1HTTRAB9AMAPT | |
| SCHEMBL9000517 | 0.79 | ALDH1A1 (0.42) | ALDH1A1HTTRAB9AMAPTMEN1 | |
| SCHEMBL26933026 | 0.78 | MAPT (0.54) | ALDH1A1ERN1HTTMAPTMEN1 | |
| SCHEMBL8568179 | 0.77 | ALDH1A1 (0.53) | ALDH1A1HTTRAB9AMAPTMEN1 | |
| SCHEMBL29955436 | 0.77 | KMT2A (0.46) | ALDH1A1ERN1MEN1KMT2ACYP3A4 | |
| SCHEMBL2600757 | 0.77 | KMT2A (0.46) | ALDH1A1ERN1MEN1KMT2ACYP3A4 | |
| SCHEMBL4899871 | 0.76 | ALDH1A1 (0.40) | ALDH1A1HTTRAB9AMAPTMEN1 | |
| SCHEMBL4899860 | 0.76 | ALDH1A1 (0.40) | ALDH1A1HTTRAB9AMAPTMEN1 | |
| Ethylene SCHEMBL27749127 | 0.74 | ALDH1A1 (0.50) | ALDH1A1HTTRAB9AMAPTMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 57 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024114658-A1 | SUBSTITUTED 1-PHENYL-3, 4-DIHYDROPYRIDO [3, 4-D] PYRIMIDIN-2-ONE DERIVATIVES | JANSSEN PHARMACEUTICA NV (BE) | 2024-06-06 | — | — | WO | disclosed |
| US-20240025856-A1 | 1,2,3,4-TETRAHYDROQUINOLINE DERIVATIVES AS INHIBITORS OF THE YAP/TAZ-TEAD ACTIVATION FOR TREATING CANCER | CISTIM LEUVEN VZW (BE) | 2024-01-25 | — | — | US | disclosed |
| US-20240025856-A1 | 1,2,3,4-TETRAHYDROQUINOLINE DERIVATIVES AS INHIBITORS OF THE YAP/TAZ-TEAD ACTIVATION FOR TREATING CANCER | CISTIM LEUVEN VZW (BE) | 2024-01-25 | — | — | US | disclosed |
| CN-116783165-A | 1,2,3, 4-tetrahydroquinoline derivatives as YAP/TAZ-TEAD activation inhibitors for the treatment of cancer | 天主教鲁汶大学 | 2023-09-19 | — | — | CN | disclosed |
| EP-3830087-B1 | HETEROCYCLIC COMPOUNDS AND THEIR USE IN PREVENTING OR TREATING BACTERIAL INFECTIONS | MUTABILIS (FR) | 2023-05-24 | — | — | EP | disclosed |
| US-11530227-B2 | Heterocyclic compounds and their use in preventing or treating bacterial infections | MUTABILIS (FR) | 2022-12-20 | — | — | US | disclosed |
| WO-2022086892-A1 | INTERLEUKIN 4 (IL4)-INDUCED GENE 1 INHIBITORS AND METHODS OF USE THEREOF | CALITHERA BIOSCIENCES, INC. (US) | 2022-04-28 | — | — | WO | disclosed |
| US-20210277019-A1 | Heterocyclic Compounds And Their Use in Preventing or Treating Bacterial Infections | MUTABILIS (FR) | 2021-09-09 | — | — | US | disclosed |
| EP-3830087-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE IN PREVENTING OR TREATING BACTERIAL INFECTIONS | Mutabilis (FR) | 2021-06-09 | — | — | EP | disclosed |
| CN-109503586-B | Dihydropteridinone BRD4 protein inhibitor, preparation method and application thereof | 郑州大学 | 2021-05-07 | — | — | CN | disclosed |
| US-7129249-B2 | Heterocyclic amide derivatives as inhibitors of glycogen phoshorylase | ASTRAZENECA AB (SE) | 2006-10-31 | — | — | US | disclosed |
| CN-1784393-A | Chemical compounds | ASTRAZENECA AB (SE) | 2006-06-07 | — | — | CN | disclosed |
| WO-2005123685-A1 | TETRAHYDROQUINOLONES AND AZA-ANALOGUES THEREOF FOR USE AS DPP-IV INHIBITORS IN THE TREATEMENT OF DIABETES | ASTRAZENECA AB (SE) | 2005-12-29 | — | — | WO | disclosed |
| WO-2005123685-A1 | TETRAHYDROQUINOLONES AND AZA-ANALOGUES THEREOF FOR USE AS DPP-IV INHIBITORS IN THE TREATEMENT OF DIABETES | ASTRAZENECA AB (SE) | 2005-12-29 | — | — | WO | disclosed |
| US-20050131015-A1 | Heterocyclic amide derivatives as inhibitors of glycogen phoshorylase | ASTRAZENECA AB (SE) | 2005-06-16 | — | — | US | disclosed |
| WO-2005020987-A1 | HETEROCYCLIC AMIDE DERIVATIVES WHICH POSSES GLYCOGEN PHOSPHORYLASE INHIBITORY ACTIVITY | ASTRAZENECA AB (SE) | 2005-03-10 | — | — | WO | disclosed |
| EP-1483270-A1 | HETEROCYCLIC AMIDE DERIVATIVES AS INHIBITORS OF GLYCOGEN PHOSPHORYLASE | Astrazeneca AB (SE) | 2004-12-08 | — | — | EP | disclosed |
| WO-2003074532-A1 | HETEROCYCLIC AMIDE DERIVATIVES AS INHIBITORS OF GLYCOGEN PHOSPHORYLASE | ASTRAZENECA AB (SE) | 2003-09-12 | — | — | WO | disclosed |
| CN-1416421-A | Novel modulators of CCR5, benzimidazole or benzotriazole | ASTRAZENE CA AB (SE) | 2003-05-07 | — | — | CN | disclosed |
| EP-0129791-A2 | Tetrahydropyridazinone derivatives, process for their preparation and their use | CASSELLA Aktiengesellschaft (DE) | 1985-01-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240025856-A1 | 1,2,3,4-TETRAHYDROQUINOLINE DERIVATIVES AS INHIBITORS OF THE YAP/TAZ-TEAD ACTIVATION FOR TREATING CANCER | YAP1, TEAD2, TEAD1 | ALDH1A1 1569/4885ERN1 2606/4885HTT 3942/4885 |
| US-20210277019-A1 | Heterocyclic Compounds And Their Use in Preventing or Treating Bacterial Infections | NQO1, ALPI, LCT | ALDH1A1 224/4885ERN1 1907/4885HTT 4378/4885 |
| US-20050131015-A1 | Heterocyclic amide derivatives as inhibitors of glycogen phoshorylase | PYGL, GYS2, GYS1 | ALDH1A1 3200/4885ERN1 385/4885HTT 565/4885 |
| US-11530227-B2 | Heterocyclic compounds and their use in preventing or treating bacterial infections | NQO1, ALPI, LCT | ALDH1A1 224/4885ERN1 1907/4885HTT 4378/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.